XOMA-213
XOMA-213 (LFA-102; X213) is a human monoclonal antibody (mAb) targeting PRLR/Prolactin Receptor. XOMA-213 inhibits hPRL-dependent growth of BaF3/hPRLR cells (EC50: 0.5 μg/mL) . XOMA-213 inhibits PRLR signaling and tumor growth in the Nb2-11-luc xenograft mouse model and the DMBA-induced rat breast cancer model. XOMA-213 can be used in Breast cancer, Hyperprolactinaemia and Prostate cancer research[1].
Product Specifications
Product Name Alternative
LFA-102; X213
UNSPSC
12352203
Target
Estrogen Receptor/ERR
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[XOMA-213]
References & Citations
[1]Damiano JS, et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther. 2013 Mar;12 (3) :295-305.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400745-500 1x 500 µL
CD45 / LCA (2B11 + PD7/26), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880204-100 1x 100 µL
Complement C4d (C4D204), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740012-500 1x 500 µL
Tyrosinase (T311), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680633-100 1x 100 µL
Von Willebrand Factor (3E2D10), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470158-500 1x 500 µL
Cytokeratin 17 (E3), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details